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Nicotinamide Riboside (NR) administration has been shown to increase fat oxidation 
and improve endurance performance in rodents, whilst recent research has proven it is 
safe for human consumption. The present study aimed to investigate the influence of 
acute NR supplementation on substrate utilisation and exercise performance in humans. 
In this counter-balanced, crossover design study, eleven recreationally-active males 
performed a 60-minute bout of cycling at 55% VO2max, followed by a 5km time-trial. 
Participants completed this twice during visits separated by at least one week, once 
following the consumption of 1000mg NR, and the other following placebo 
consumption. The contribution of fat oxidation to total substrate utilisation was not 
significantly different between the NR and placebo conditions during steady-state 
exercise (22.3±9.0% and 19.6±7.3%, respectively; p < 0.05). Similarly, there were no 
significant differences shown between 5km time-trial performance with NR 
(823.4±250.0 seconds) and placebo (819.5±239.8 seconds). To conclude, a single dose 
of NR does not influence substrate utilisation during moderate-intensity exercise, nor 
does it enhance exercise performance. Future research should investigate the effects of 
chronic NR supplementation, or the coupling of this with exercise training to further test 
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Regular physical activity is a preventative strategy for various chronic diseases such as 
type 2 diabetes, cardiovascular disease, hypertension and obesity (Warburton, Nicol & 
Bredin, 2006). Performing repeated bouts of exercise will, over time, induce various 
physiological adaptations that also facilitate an improvement in exercise performance 
(Jones & Carter, 2000). The type of training undertaken, such as endurance or 
resistance, determines the nature and magnitude of these changes (Jones & Carter, 
2000).  
Joyner & Coyle (2008) present a model of the multiple physiological factors that 
interact as determinants of performance (see Figure 1). Ultimately, they propose that 
exercise performance is determined by a combination of mechanical, cardiovascular, 
molecular, respiratory and anthropometric factors. The model suggests that 
morphological components such as stroke volume, haemoglobin content, aerobic 
enzyme activity and skeletal muscle fibre type together determine whole-body 
performance markers, such as maximal oxygen consumption (VO2max), lactate 
threshold, mechanical efficiency and buffering capacity. These markers then interact at 
the whole-body level to determine the velocity and/or power of any given activity 
performed (Joyner & Coyle, 2008). Thus, changing any of these components has the 
















An additional factor that also influences performance is the contribution of fuels used 
during exercise. It is well known that carbohydrates (CHO) and fats are the dominant 
substrates oxidised in skeletal muscle during exercise in humans (Spriet, 2002), with a 
very minor contribution from protein. In comparison to CHO, fat is much more energy 
dense and is largely stored within the body – primarily in adipose tissue and as 
triglycerides within the muscle (Spriet, 2002). Following food consumption, 
macronutrients themselves do not directly provide energy – they require oxidation 
which releases adenosine triphosphate (ATP), and finally energy for work is released 
once ATP is hydrolysed (Melzer, 2011). The magnitude of energy expenditure, i.e. the 
intensity of exercise, is a determinant of whether this energy is generated anaerobically 
Figure 1. Schematic of the determinants of 







































Efficiency ( ) + 
3 
 
or aerobically. During light exercise, aerobic respiration almost solely provides the 
energy required, however as this intensity increases, reliance on the anaerobic system 
becomes greater (Melzer, 2011). Although the oxidation of CHOs and fats occurs 
simultaneously, their contribution is largely dependent on various factors including 
exercise duration, exercise intensity, training status and nutrition (Venables, Achten & 
Jeukendrup, 2005). In an endurance trained state, fat oxidation at a given intensity is 
heightened, which corresponds with enhanced performance (Holloszy & Coyle, 1984). 
 
FACTORS AFFECTING SUBSTRATE UTILISATION 
The most thoroughly researched and seemingly important determinant of substrate 
utilisation is exercise intensity. In general, fat utilisation increases from low to moderate 
intensity exercise, and decreases from moderate to high intensities (Achten & 
Jeukendrup, 2003). Various studies have compared oxidation rates at different workload 
intensities, with results supporting this statement. In an early study by Romjin et al. 
(1993), five endurance-trained athletes completed three bouts of exercise on three 
consecutive days in a randomised order – one for 120 minutes at 25%VO2max, another 
for 120 minutes at 65%VO2max, and the third for just 30 minutes at 85%VO2max. 
Exercise intensity and CHO oxidation rates displayed a significant positive relationship, 
however the reverse was not seen with fat oxidation. It was reported that after 30 
minutes, fat oxidation rates were significantly higher at 65%VO2max compared to both 
the lower and higher intensities. In fact, plasma free fatty acid (FFA) values were shown 
to persistently decrease at 85%, whereas a steady increase was observed with the 
moderate-intensity bout (Romjin et al., 1993). 
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Similarly in a later study, three consecutive 30-minute bouts of cycling were completed 
by eight participants, at 40%, 55% and finally 75%Watt max (Van Loon et al., 2001), 
with results indicating that whole-body fat oxidation was higher at 55%Wmax 
compared to 40%, with the lowest rates reported during exercise at 75%Wmax. 
However, total CHO oxidation was significantly higher with this increased intensity 
(Van Loon et al., 2001). 
  
FATMAX 
The exercise intensity at which the maximal fat oxidation rate occurs has been deemed 
‘Fatmax’. Various groups have attempted to determine this exact intensity, however this 
has proven difficult as it appears that the variation between individuals is large 
(Venables, Achten & Jeukendrup, 2005). Despite this, it has been reported that the 
majority of individuals’ Fatmax occurs at a moderate-intensity exercise, ranging from 
40%VO2max up to 72%VO2max (Bergman & Brooks, 1999; Achten, Gleeson & 
Jeukendrup, 2002a). 
Achten, Gleeson & Jeukendrup (2002a) conducted a study in order to develop a test 
protocol to determine at which intensity Fatmax occurs. A set of incremental exercise 
tests with varying stage lengths and increment sizes were compared, with no significant 
differences in Fatmax shown between these. Furthermore, using intensities that 
corresponded to those in the incremental tests, various continuous prolonged exercise 
bouts at constant work rates were performed. In this study, the maximal rate of fat 
oxidation was calculated at, on average, 64±4 %VO2max, with a Fatmax zone deemed 
between 55±3 % and 72±4 %VO2max (Achten, Gleeson & Jeukendrup, 2002a). 
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The most time-efficient of the tested protocols from the study by Achten, Gleeson & 
Jeukendrup (2002a) was followed in a much larger study (Venables, Achten & 
Jeukendrup, 2005), in which 157 men and 143 women completed an incremental test to 
exhaustion on a treadmill, with intensity increasing every three minutes, then every one 
minute once RER reached a value of 1. The average intensity at which Fatmax occurred 
at in this study was lower in comparison, at 48.3%VO2max. However, the intensity at 
which Fatmax occurred in two more recent studies also following this same protocol 
differed from this, at 53±15%VO2max in 281 student athletes (Randell et al., 2017) and at 
60±16%VO2max in 305 healthy volunteers (Fletcher et al., 2017), highlighting the large 
variability seen in this measure. 
The intensity that Fatmax occurs at has also been associated with the onset of plasma 
lactate accumulation, with a significant correlation shown between the two when 26 
male cyclists performed a graded test to exhaustion on a cycle ergometer (Achten, 
Gleeson & Jeukendrup, 2002b). Similar results were displayed in a later study by 
Achten & Jeukendrup (2004), in which it was concluded that there is a strong 
relationship between the onset of the decline in fat oxidation and the initial lactate 
increase above baseline during incremental exercise. Hence, at intensities below Fatmax 
(low or moderate-intensity exercise), lactate levels will likely remain at basal level.  
 
CONTROL OF SUBSTRATE UTILISATION 
Performing regular exercise is one way in which to alter an individuals’ fat and CHO 
metabolism, with studies reporting that fat oxidation levels during exercise have 
increased by up to 44% in obese participants (Venables & Jeukendrup, 2008), and 29% 
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in healthy, non-obese participants (Schrauwen et al., 2002) after 4 and 12 weeks of 
training, respectively. In both studies, training sessions consisted of continuous exercise 
at a low-to-moderate intensity, and both also reported decreased CHO oxidation levels 
post-training.  
As aforementioned, various studies have also demonstrated a change in the oxidation 
rates of fat and CHO during a single bout of exercise (Romjin et al., 1993; Van Loon et 
al., 2001), albeit largely dependent on exercise intensity and duration. The preference of 
substrate and the rate of substrate utilisation in skeletal muscle during these acute bouts 
is regulated by hormonal, metabolic and neural mechanisms (Esséen, 1977). 
 
HORMONAL CONTROL OF SUBSTRATE UTILISATION 
Collectively, hormones are involved in the regulation of many fundamental processes 
such as circulation, reproduction, growth and development, and metabolism (Galbo, 
1986). Acute energy stress is a primary factor in hormone secretion, with marked 
changes observed in numerous hormones in response to stressors such as physical 
activity (Galbo, 1986). During times of stress, such as an acute exercise bout, the 
concentration of hormones that enhance lipolysis, glycolysis and gluconeogenesis rises 
(Bunt, 1986), emphasising their importance in regulating substrate metabolism.  
Energy metabolism specifically is regulated primarily by the catecholamines, insulin, 
cortisol, glucagon and growth hormone (Bunt, 1986). The transition from rest to 
exercise causes the secretion of catecholamines, initiating the mobilisation of FFAs and 
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glucose. This response subsequently causes the release of secondary hormones, which 
then apply their actions to specific receptors on target cells (Bunt, 1986).  
The catecholamines - adrenaline and noradrenaline - play an important role in 
controlling the metabolism of fats and CHOs, as well as stimulating the cardiac, 
respiratory and thermoregulatory systems (Zouhal et al., 2008). With exercise, 
catecholamine concentration rises proportionately with increased intensity and duration 
(Banister & Griffiths, 1972; Galbo, Holst & Christensen, 1975; Nilsson et al., 1975). 
Banister & Griffiths (1972) studied the effects of four different exercise intensities in 
five participants, and showed a progressive relationship between catecholamine 
concentrations and workload intensity/VO2. Similar results were reported by Nilsson et 
al. (1975), where six healthy males completed a bout of exercise in which workload was 
increased every five minutes, for 15 minutes in total. A distinct increase in both 
noradrenaline and adrenaline concentrations were observed after 10 and 15 minutes, and 
these rises correlated with heart rate and mean blood pressure.  
The increase in catecholamine secretion seen during exercise results in increases in 
glycogen utilisation and lipolytic rate. The infusion of adrenaline throughout a 40-
minute cycle at 71%VO2peak resulted in a rise in RER and net glycogen utilisation 
(Febbraio et al., 1998), whilst the inhibition of catecholamine secretion using a beta-
adrenoceptor blockade was shown to reduce the exercise-induced rise in FFA 
concentrations during submaximal exercise (Hall et al., 1987), and glycerol during 30 
minutes of cycling at ~66%Wmax (Arner et al., 1990).  
On the contrary, plasma insulin concentration decreases during physical activity, and is 
inhibited by sympathetic nerves (Galbo, 1986). With an increase in both duration and 
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intensity, the inhibition of insulin secretion rises (Galbo, 1986). High levels of insulin 
during exercise would be counter-productive, as insulin works to enhance the synthesis 
of both fat and glycogen, and lower blood glucose levels (Bunt et al, 1986). Therefore, 
when insulin secretion is inhibited during exercise, the rate of lipolysis is accelerated, 
providing more glycerol and FFAs to be utilised (Wasserman et al., 1989). 
 
MOLECULAR CONTROL OF SUBSTRATE UTILISATION  
At the molecular level, this enhanced fat oxidation is the downstream result of the 
upregulation of various transcription factors (TF), co-activators and enzymes (Gerhart-
Hines et al., 2007), as depicted in Figure 2. Both acute exercise bouts and long-term 
training can induce these changes (Pilegaard, Saltin & Neufer, 2003; Russell et al., 
2003), and the coactivator peroxisome proliferator-activated receptor (PPAR)-y 
coactivator-1α (PGC-1α) appears to play arguably the most important role. Deemed the 
‘master regulator of mitochondrial biogenesis’, PGC-1α has the ability to control the 
activity of several TFs, such as PPARs and estrogen-related receptors (ERRs) (Vega, 
Huss & Kelly, 2000; Schreiber et al., 2004), both regulators of the FA oxidation 
pathway (Finck & Kelly, 2006).  
The overexpression of PGC-1α in mice was investigated during both voluntary and 
forced exercise, then compared to wild-type (WT) controls (Calvo et al., 2008). Not 
only did PGC-1α overexpression allow mice to run significantly further, faster, and for 
longer, they also elicited a 24% increase in VO2peak. RER values observed were 
significantly lower at higher running speeds with overexpression, and the authors 
therefore propose that these mice were proficient at sparing CHO stores and hence were 
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utilising more FAs. Consistent with this result, analysis of muscle revealed elevated 
expression of FA transport/oxidation genes such as CD36, FA binding protein 3 
(FABP3) and FA transport protein 1 (FATP1) in the PGC-1a overexpressed mice. It is 
plausible to propose that by upregulating PGC-1a via activation of its upstream targets 
during scenarios such as exercise or diet manipulation, that these same changes would 
occur.  
PGC-1α itself is regulated by various pathways that are activated in response to 
different stimuli, namely energy stressors such as exercise and fasting (Fernandez-
Marcos & Auwerx, 2011). Increased calcium levels, p38 mitogen-activated kinase (p38 
MAPK) activation (Akimoto et al., 2005) and a heightened AMP/ATP ratio are all 
responses that occur due to a change in energy status following exercise, and they each 
initiate a number of mechanisms that induce the expression of PGC-1α. AMP-activated 
protein kinase (AMPK) is a fundamental energy sensor that is activated when there is a 
rise in the AMP/ATP ratio, and activates PGC-1α via phosphorylation (Fernandez-
Marcos & Auwerx, 2011). When AMPK is activated acutely, glycogen and protein 
synthesis are suppressed, whilst glucose transport and fat metabolism are stimulated 
(Carling & Hardie, 1989; Bolster et al., 2002; Merrill et al., 1997; Winder & Hardie, 
1996). 
Another key energy sensor that when activated induces PGC-1α expression, is SIRT1. 
This well-researched member of the sirtuin family is also activated during times of 
energy stress, and upregulates PGC-1α via deacetylation (Fernandez-Marcos & Auwerx, 
2011). Sirtuins are nicotinamide adenine dinucleotide (NAD)+-consumers, and require 













An important, additional factor influencing substrate metabolism and hence 
performance, is nutrition. Historically, research has focussed largely on the importance 
of CHO intake on performance. Krogh & Lindhard (1920) first established in human 
participants that exercising following the consumption of a high-CHO diet felt easier 
than following a high-fat diet. A few years later, it was shown that a decrease in blood 
glucose concentration was a hindrance to performance, yet that consuming CHOs 
prevented this decrease and therefore aided marathon running performance (Levine, 
Gordon & Derick, 1924). The relationship between CHO intake and muscle glycogen 
was first reported by Bergstrom et al. (1967), when it was shown that consuming a high-
CHO diet increased muscle glycogen levels and hence enhanced one’s capacity to 
complete prolonged bouts of exercise.  





FATTY ACID OXIDATION 
Figure 2. Molecular control of fat oxidation 
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Following this discovery, studies investigating the effects of high CHO intake were in 
abundance, with new strategies emerging aiming to enhance glycogen stores prior to 
exercise. The classic approach to CHO loading for endurance events was studied first by 
Bergstrom et al. (1967), however a number of years later, Sherman et al. (1981) 
proposed a shorter, modified protocol involving a more gradual decrease in training 
coupled with an increase in CHO consumption. This protocol was later challenged by 
Bussau et al. (2002), who proved that just one day of high CHO intake resulted in 
maximal muscle glycogen content. Participants in this study were however endurance-
trained athletes, so results may not be applicable to the general population. 
Until more recently, research regarding the enhancement of fat oxidation via nutrition 
was limited. This is surprising, as the promotion of fat utilisation during endurance 
exercise should, in theory, slow the rate at which muscle glycogen is depleted and hence 
enhance exercise performance (Hawley, Brouns & Jeukendrup, 1998). Various 
nutritional strategies aiming to achieve heightened fat oxidation have been explored, 
including the ingestion of different supplements, the intake of fat before/during 
exercise, and the consumption of high-fat, low-CHO diets (Hawley, Brouns & 
Jeukendrup, 1998).  
Despite efforts from several research groups, the ingestion of both medium- and long-
chain triglycerides prior to and during exercise produced no significant effects on fat 
oxidation or exercise performance (Ivy et al., 1980; Satabin et al., 1987; Jeukendrup et 
al., 1995). Studies investigating the consumption of short-term (3 to 7 days) high-fat 
diets did however yield interesting results. When a five day high-fat diet was compared 
to a five day high-CHO diet, Jansson & Kaijser (1982) reported that following the high-
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fat diet, fat oxidation was enhanced, however no evidence of glycogen sparing was 
distinguished during a 25-minute bout of cycling. On the contrary, long-term (>7 day) 
high-fat diets appear to increase fat oxidation levels without any detrimental effects on 
performance. Following 14 days of consuming a high-fat diet, trained cyclists 
performed significantly better in a moderate-intensity time to exhaustion test than after a 
high-CHO diet, despite beginning with lower muscle glycogen content (Lambert et al., 
1994). This performance enhancement was accompanied by an increase in fat oxidation 
rates and a subsequent decrease in CHO oxidation rates.  
 
NUTRITIONAL SUPPLEMENTS  
The use of nutritional supplements to enhance fat utilisation is a thriving area of 
research, with this group of supplements often referred to as ‘fat burners’ (Jeukendrup 
& Randell, 2011). One substance that has received a great deal of attention is caffeine. 
Despite the vast number of studies that have investigated the effects of this supplement, 
results still appear to be inconclusive regarding its effects on fat oxidation. In an early 
study by Costill et al. (1978), trained cyclists were administered with caffeinated coffee 
60 minutes prior to a bout of exercise to exhaustion at 80%VO2max. Compared to a 
decaffeinated control, participants exhibited significantly increased fat oxidation during 
exercise, and this was supported by increased measurements of plasma FFAs and 
glycerol, and a decrease in RER. These results prompted the proposal of the theory that 
caffeine could enhance exercise capacity by increasing and decreasing fat and CHO 
oxidation, respectively, hence promoting glycogen sparing leading to enhanced 
endurance (Graham et al. 2008). However, it has more recently been proposed that 
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central mechanisms are more likely the cause of this, with evidence that caffeine 
increases the activity of the sympathetic nervous system, hence increasing adrenaline 
levels which can increase FA availability (Jeukendrup & Randell, 2011). In contrast 
however, numerous studies have also shown that caffeine has no significant effect on fat 
and CHO metabolism during exercise compared to a placebo, with measures such as 
RER and glycogenolysis remaining unchanged (Graham et al., 2000; Jackman et al., 
1996). Additionally, one study has shown a tendency towards increased activity of 
muscle glycogen phosphorylase following caffeine ingestion (Chelsey et al., 1998), 
which should promote glycogenolysis and hence enhance CHO metabolism rather than 
reduce it. 
Another supplement of interest in this area is green tea extract (GTE). The first study to 
explore how GTE effects fat utilisation at rest was conducted by Dulloo et al. (1999), 
who showed a significant increase in 24-hour fat oxidation following GTE consumption 
in comparison to caffeine and a placebo. However, a later study by Berube-Parent et al. 
(2005) reported no differences in fat oxidation between GTE and a placebo, despite 
finding an 8% increase in 24-hour energy expenditure. Supplementing GTE prior to 
exercise has produced similar ambiguous results. One study investigated the effects of 
GTE ingestion prior to a 30-minute cycle at 50%Wmax, finding positive results 
(Venables et al., 2008). Whole-body fat oxidation increased significantly with GTE, and 
the contribution of fat was 17% higher compared to placebo supplementation. However, 
a later study saw lower fat oxidation during a 60-minute cycle at 60%VO2max following 
six days of supplementation, compared to caffeine and a placebo (Dean, Braakhuis & 
Paton, 2009), indicating that further research into this supplement may be necessary to 
confirm its effects on metabolism.  
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Very recently, an additional supplement with the potential to influence substrate 
metabolism has been discovered. Nicotinamide Riboside (NR) is a naturally occurring 
substance found in cow’s milk (Bieganowski & Brenner, 2004), although it can also be 
obtained from unprocessed foods such as meat, eggs and green vegetables. NR is a form 
of vitamin B3, and works as an NAD+ precursor, meaning its consumption has the 
potential to increase NAD+ levels in various tissues. 
 
NAD+  
NAD+ is a cellular coenzyme, whose keystone function, along with its reduced form, 
NADH, was initially identified as inducing hydrogen transfer in metabolic oxidation-
reduction reactions (Berger, Ramirez-Hernandez & Ziegler, 2004). More recent studies 
have revealed that NAD+ is also associated with additional reactions, acting as a co-
substrate for various enzymes such as poly-ADP-ribose polymerases (PARPs) (Bai & 
Canto, 2012) and sirtuins (Houtkooper et al., 2010).  
Oxidation-reduction reactions are essential to numerous metabolic pathways such as 
glycolysis, the Kreb’s cycle, oxidative phosphorylation and anaerobic metabolism 
(Berg, Tymoczko & Stryer, 2002). NAD+ is an electron carrier, and when reduced to 
NADH, this electron can be transferred to other transported molecules – ultimately to 
deliver the electron to oxygen - via the above pathways (Berg, Tymoczko & Stryer, 
2002). NAD+ and NADH together hence play a major role in the synthesis of ATP from 
various dietary sources (White & Schenk, 2012).   
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Alterations in NAD+ levels have the potential to change the activity of various enzymes 
involved in important metabolic pathways (Imai, 2009). As the amount of NAD+ is 
limited in a cell, it must be regenerated via the re-oxidation of NADH for these 
pathways to ensue (Berg, Tymoczko & Stryer, 2002). The balance of the oxidation-
reduction state of NAD+ and NADH was previously assumed to determine the 
NAD+/NADH ratio, however the discovery of the biosynthetic and salvage pathways of 
NAD+ and the actions of NAD+-consumers has enhanced the complexity of this ratio 
greatly (White & Schenk, 2012). 
 
NAD+ CONCENTRATIONS 
NAD+ is primarily located within three cellular compartments – the cytosol, the 
nucleus, and the mitochondria (White & Schenk, 2012). The total NAD+ and NADH 
concentrations in skeletal muscle have been estimated at ~1.5-1.9 and ~0.08-
0.2mmol/kg dry muscle, respectively (Graham et al. 1978). However, the way in which 
this is distributed between each compartment varies greatly; in the cytosol, values have 
been reported at around 0.15 and 0.00028mmol/kg wet muscle, and in the mitochondria, 
values are much higher at 3.15 and 0.5mmol/kg wet muscle (Cabrera et al., 1998). In 
general, little is known about nuclear NAD+ levels, although it is thought that the 
cytosolic and nuclear compartments are in equilibrium, and hence this coenzyme can 
pass freely through these membranes (Easlon et al., 2008).  
To enable the movement of NAD+/NADH into the mitochondria however, shuttles are 
required due to the impermeability of the mitochondrial membrane (Palmieri, 2004). In 
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skeletal muscle, the glycerol 3-phosphate and malate-aspartate shuttles allow for this 
movement (White & Schenk, 2012). 
 
NAD+ AND EXERCISE 
Intracellular NAD+ levels increase in response to energy stressors, such as low glucose 
levels and exercise (Gerhart-Hines et al., 2007). In early animal studies, it was 
concluded that in mammalian muscle, this rise predominantly occurred within the 
mitochondria (Jobsis & Stainsby 1968). In human studies however, results are 
conflicting regarding NAD+/NADH action at various exercise intensities. Graham et al. 
(1978) measured muscle NAD+ at rest and following a bout of cycling at both ~75% 
and ~100% VO2max. Following work at both of these intensities, muscle NAD+ content 
significantly decreased. Conversely, in a later study, both NAD+ and the cytosolic 
NAD+/NADH ratio increased above resting levels at these same intensities (Sahlin et 
al., 1987).  
 
NAD+ CONSUMERS 
Both the synthesis and breakdown of NAD+ influences its abundance within a cell. 
NAD+ acts as a co-substrate for three types of enzymes – sirtuins, poly-ADP-ribose 
polymerases (PARPs) and cADP-ribose synthases – these each consume NAD+ and 




Sirtuins act as both transcriptional activity effectors and energy sensors, through their 
ability to control the acetylation state of transcriptional regulators, such as histones 
(Houtkooper et al., 2012). Sirtuins are NAD+-dependent, and when activated they 
trigger pathways that enhance mitochondrial oxidative metabolism and metabolic 
efficiency (Imai & Guarente, 2014). Although the sirtuin family consists of seven 
different proteins (SIRT1-SIRT7), SIRT1 and SIRT3 are the most widely studied and 
seemingly important of these (North & Verdin, 2004).  
When PARPs consume NAD+, this is either to cause an ADP-ribosyl protein 
modification or to create the ADP-ribose polymer, PAR (Bai & Canto, 2012). PARP 
activity is upregulated by breaks in DNA strands (Malanga & Althaus, 2005), and plays 
a role in transcriptional regulation, cell division and energy metabolism (Schreiber et 
al., 2006).  
 
NAD+ BIOSYNTHESIS 
NAD+ is synthesised from smaller units, either via the de novo or salvage pathways (see 
Figure 3). De novo synthesis is an eight-step process and begins with the amino acid 
tryptophan, which is, in short, converted into quinolinic acid, then into nicotinic acid 
mononucleotide (NAMN). NAMN is then adenylated to form nicotinic acid adenine 
dinucleotide (NAAD+), which is finally converted to NAD+ by the enzyme NAD+ 
synthase (Bogan & Brenner, 2008). NAD+ can also be generated from the salvageable 
precursor vitamins nicotinic acid (Na), nicotinamide (Nam) and NR. As detailed below 
in Figure 3, fewer steps are required to rebuild NAD+ from these precursors. Alongside 
tryptophan, each of the precursors is available through one’s diet, and hence dietary 
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manipulation can impact NAD+ levels. However, as tryptophan plays a role in various 
other biosynthetic processes, its efficiency is limited in comparison to the salvage 





DEPLETED NAD+ LEVELS 
Nam and Na are collectively termed niacin, which is essentially the vitamin form of 
NAD+ (vitamin B3). Dietary intake of niacin, NR and/or tryptophan prevent pellagra, a 
disease carrying symptoms such as dermatitis, diarrhoea and dementia (Bogan & 
Brenner, 2008). A lack of niacin was determined as the cause of this disease, hence why 
eating foods containing high levels of this vitamin (e.g. milk, eggs and meat) acted as a 
cure (Bogan & Brenner, 2008). Another condition associated with depleted NAD+ 
levels is dyslipidemia, which involves the elevation of triglycerides in the blood 
(Ratajczak et al., 2016). As Nam can inhibit sirtuin activity and is hence less efficient at 
lowering these lipid levels, high doses of Na are often prescribed to prevent and treat 
Figure 3. NAD+ biosynthesis 









dyslipidemia (Ratajczak et al., 2016). Although successful, these doses cause painful 
flushing as a side effect, as a result of the activation of the GPR109A receptor (Wise et 
al., 2003). It is believed however, that the effectiveness of Na is likely due to its ability 
to increase NAD+ levels, which can also be achieved by another vitamin precursor that 
does not activate GPR109A and hence gives rise to no adverse side effects – NR (Canto 
et al., 2012). 
 
NICOTINAMIDE RIBOSIDE 
Prior to 2004, it was believed that niacin was the only dietary NAD+-precursor 
available. However, Bieganowski & Brenner (2004) discovered that in yeast, NR is also 
an effective precursor that enables NAD+ biosynthesis. Unlike niacin, NR is unique as 
it directly enhances the synthesis of NAD+ via the nicotinamide riboside kinase (NRK) 
pathway in skeletal muscle (Bieganowski & Brenner, 2004). Once NR enters the cell it 
is first phosphorylated to NMN by these NRKs, and NMNAT then converts this into 
NAD+ (Belenky, Bogan & Brenner, 2007).  
Following the initial discovery of NR and its pathways, Belenky et al. (2007) went on to 
investigate the effects that exogenous NR had on WT yeast cells, rather than modified 
cells with gene deletions as had been examined previously (Bieganowski & Brenner, 
2004). It was discovered that intracellular NAD+ levels in yeast cells were doubled with 
the addition of 10μM NR, however only when grown in Na-free media. This 
supplementation also significantly prolonged lifespan in both WT and mutant strains, in 
comparison to those strains that were NR-deficient and showed no extension in lifespan. 
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Based on the mechanisms by which NR works, much research has investigated whether 
the use of this vitamin would be beneficial in various clinical populations. Mice with 
Alzheimer’s (Gong et al. 2013), noise-induced hearing loss (Brown et al. 2014), 
mitochondrial myopathy (Khan et al. 2014), muscular dystrophy (Ryu et al. 2016) and 
type 2 diabetes (Yoshino et al. 2011) have all shown improvements following NR 
administration, albeit some more pronounced than others.  
The first study to provide evidence for the effects NR has on skeletal muscle was 
conducted by Canto et al. (2012), where mammalian cells and mouse tissues were 
supplemented with NR, and the effects of this on oxidative metabolism and high-fat 
diet-induced obesity were assessed. This study was designed on the premise that 
increased NAD+ levels leads to enhanced sirtuin (specifically SIRT1 and SIRT3) 
activity, which in turn may lead to protection against metabolic diseases and may also 
heighten fat oxidation (Pfluger et al., 2008). Firstly, mice and human cells were treated 
with NR, with reports that NAD+ content was significantly enhanced in muscle and 
liver cells, and importantly, in the mitochondria. In response to this increase in NAD+, 
enhanced deacetylation of both SIRT1 and SIRT3 targets were seen in skeletal muscle, 
liver and brown adipose tissue cells in vivo, and hence, increased acetylation of PGC-1a 
was also observed. The effect of NR on mice consuming a normal chow diet and mice 
consuming a high-fat diet were compared following this, producing positive results. 
Although NR had no effect on body weight in mice on the chow diet, those on a high-
fat diet showed a decrease in weight gain due to reduced fat mass. It was confirmed that 
this decrease was due to enhanced energy expenditure, which was linked to heightened 
oxygen consumption rates with NR administration. These results are promising for 
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future research looking into NR and exercise, as an increase in oxygen consumption 
should correlate with improvements in performance (Joyner & Coyle, 2008). 
However, as shown in a recent study by Kourtzidis et al. (2016), it appears that NR 
supplementation has the opposite effect on exercise performance. Following 21 days of 
NR supplementation (300mg/kg BW/day), nine Wistar rats completed an incremental 
swimming performance test, in which they swam until exhaustion under an incremental 
load in warm water. Although results were not significant, the NR group tended towards 
a poorer physical performance by 35% in comparison to control rats. This protocol 
however initiated a survival response mechanism, as the rats were swimming to avoid 
drowning. It is possible that use of an alternative exercise mode would produce 
opposing results, as was seen with enhanced treadmill running performance in mice 
administered with NR (Canto et al., 2012). More research into the relationship between 
NR and exercise performance would provide a clearer insight into whether this 
supplement has the potential to be performance enhancing.  
 
NR SUPPLEMENTATION IN HUMANS 
Until recently, NR administration had only been investigated in yeast, mammalian cells 
and rodents. However, Trammell et al. (2016) conducted the first human trial in the 
form of a pilot study in one healthy, male participant, in which the participant 
supplemented with 1,000mg of NR daily, for seven days. Frequent blood samples were 
taken in the hours following ingestion of the first dose, and analysis showed that NAD+ 
levels peaked 7.7 hours post-ingestion (2.7-fold increase from baseline), with no 
changes seen in the first 2.7 hours (see Figure 4 for the PBMC NAD+ blood response). 
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Consistent with previous NR literature, no adverse side-effects were observed 
throughout or following the supplementation period.  
 



















This pilot study provided confirmation that NR is effective, and safe for human 
consumption, leading to the conduction of the first clinical trial in humans (Trammell et 
al., 2016). Twelve healthy participants (six male and six female) were recruited to 
establish whether NR works in a dose-dependent manner, and hence each orally 
consumed a single dose of 100mg, 300mg and 1,000mg NR in a randomised order, with 
a seven day washout period between each. After analyses of various NAD+ metabolites, 
Figure 4. PBMC NAD+ concentration with respect to whole blood volumes following 
consumption of 1,000mg NR daily for seven days in one healthy, male participant (data from 
Trammell et al. 2016). 
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it was concluded that NR works dose-dependently, with the greatest rise in NAD+ 
































NR DOSING STRATEGIES 
The optimal dosing strategy of NR is currently unknown, with rodent studies having 
only studied NR in a chronic fashion, and in clinical populations such as in models with 
obesity (Canto et al., 2012), diabetes (Yoshino et al., 2011) and mitochondrial 
myopathy (Khan et al., 2014).  
However, a recent study investigated the effects of a range of NR concentrations in 
mice consuming a mildly obesogenic diet, with metabolic flexibility as the main 
outcome measure (Shi et al., 2017). This study was designed not only because the 
authors believed the NR doses used in previous studies appeared “strikingly high 
Figure 5. NAD+ metabolite AUC increase from baseline (%) in response to 100mg, 300mg 
and 1,000mg doses of NR in 12 participants (data from Trammell et al. 2016). 
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compared to most commercial supplements”, but also because the benefits of vitamin 
B3 on metabolic health are currently unidentified (Shi et al., 2017). NR doses ranging 
from to 5 to 900mg/kg of diet (5NR, 15NR, 30NR, 180NR and 900NR) were 
administered in nine-week old mice for a 15 week supplementation period. Despite the 
900NR dose being significantly higher than all other administered doses, no differences 
were reported in serum or liver levels of NR, tryptophan or Nam when compared to the 
15, 30 or 180NR doses. The gene expression of NR pathway enzymes (NRK1/2, 
NAMPT and NMNAT) in skeletal muscle, liver and white adipose tissue also displayed 
no variation with changes in dose. Results showed that with 30NR, fasting metabolic 
flexibility was significantly enhanced in comparison to 5NR, and refeeding metabolic 
flexibility was also significantly greater compared to 5NR, 15NR and 900NR 
respectively. This dose also exhibited the highest expressions of PGC-1a and PPARγ, 
both key mitochondrial genes that play important roles in fat metabolism. 
Although lacking in depth, the research looking at NR consumption in humans appears 
to promote the daily dose of 1,000mg NR for the greatest effects on the NAD+ 
metabolome (Trammell et al., 2016). However, the length of the supplementation period 
required to optimally induce these changes needs further investigation.  
 
Whilst the evidence surrounding NR administration in cells and rodents is fairly 
extensive, with many studies reporting the clear benefits of this supplement, research in 
human participants is lacking. This opens the door to an exciting realm of study into 
how NR consumption may affect various human clinical populations, or even if it has 
the capacity to work as a performance-enhancing supplement.  
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An increase in NAD+ levels heightens the NAD+/NADH ratio, which has the potential 
to enhance the enzymatic activity of SIRT3 (Hirschey et al., 2010). Upregulating SIRT3 
expression results in increased deacetylation of various metabolic enzymes including 
those involved in beta-oxidation, and can subsequently enhance fat oxidation (Hirschey 
et al., 2010). With evidence in mice that NR supplementation enhances NAD+ levels, 
boosts sirtuin activity and hence improves oxidative capacity and mitochondrial 
function (Canto et al., 2012), together with the confirmation from Trammell et al., 
(2016) that consumption of a single dose of NR significantly increases NAD+ levels in 
human participants, it is viable to suggest that NR administration has the potential to 
promote fat oxidation in humans. Acute bouts of moderate-intensity exercise also have 
the ability to increase fat oxidation, via various hormonal, metabolic and neural 
pathways. Hence, the present study aims to investigate whether the consumption of NR 
prior to an acute bout of steady-state exercise will have an added effect on whole-body 
fat oxidation, in comparison to a placebo. 
An increase in fat oxidation during a bout of steady-state exercise should also, in theory, 
enhance one’s performance in a higher intensity time-trial immediately post-exercise, 
via muscle glycogen sparing. Elevated levels of glycogen spared during the steady-state 
exercise should provide more glycogen for the latter stages of the performance, perhaps 
allowing one to produce a higher power output for longer and complete the time-trial 
more rapidly. Hence, following the steady-state exercise bout, the present study will 
also include a 5km time-trial performance test in order to compare exercise performance 
following both NR and placebo consumption. 
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It should however be noted that muscle glycogen sparing is not certain. Despite the 
hypothesis put forward by numerous researchers that CHO consumption during 
moderate-intensity exercise will reduce the rate of muscle glycogenolysis and hence 
improve performance, the literature surrounding this mechanism indicates that 
utilisation of muscle glycogen is not consistently reduced with CHO consumption 
(Karelis et al., 2010).  
 
HYPOTHESES 
1. Nicotinamide riboside supplementation will promote enhanced fat oxidation 
during a bout of steady-state exercise compared to a placebo trial. 
2. Nicotinamide riboside supplementation will improve time-trial performance 














Eleven healthy, young males volunteered to participate in this study (see Table 1 for 
participant characteristics). All participants were recreationally active, achieving the UK 
government physical activity guidelines for adults (150 minutes of moderate intensity, 
or 75 minutes of vigorous intensity activity per week), however were excluded if they 
were specifically endurance-trained athletes. Inclusion criteria required participants to 
be aged between 18 and 35, have a body mass index (BMI) between 18 and 30kg/m2, 
and a VO2max below 60mL/kg/min. This latter value was determined during the 
participant’s first visit to the laboratory following the completion of an incremental 
exercise test on a cycle ergometer (Lode Excalibur Sport, Groningen, Netherlands). In 
addition to not fulfilling the inclusion criteria, participants were also excluded from 
participating in the study if they were: currently taking part in another study; consuming 
a high-fat, low-carbohydrate diet; answered ‘yes’ to any questions on the health 
screening form (e.g. history of elevated blood pressure, heart condition, chest pain, 
elevated blood cholesterol, asthma, diabetes, hepatitis, bleeding disorders); had a past 
history of substance abuse, smoking or was taking medicine/supplements that may 
influence normal metabolic processes; or finally, had donated blood within twelve 
weeks of the study commencing.  
Ethical approval was granted by the University of Birmingham's School of Sport, 




Table 1. Participant characteristics  
Variable n=11 
Age (years) 24.91±2.34 
Weight (kg) 77.86±5.89 
Height (cm) 181.36±8.51 
VO2max (ml/kg/min) 43.8±6.50 
Values are means ± S.D.   
 
STUDY DESIGN 
This was a single-centre study with a randomised, counter-balanced, crossover, double-
blind design. Participants were required to visit the Human Performance Laboratory in 
the School of Sport, Exercise and Rehabilitation Sciences at the University of 
Birmingham on five separate occasions, over a period of approximately four weeks. 
Visit 1 consisted of the completion of a health and activity questionnaire, the 
determination of anthropometric measures (height and weight), and the signing of 
informed consent. If eligible thus far based on the inclusion/exclusion criteria, 
participants then performed an incremental test on a cycle ergometer to determine 
VO2max. Visits 2 and 3 acted as familiarisation trials for the 5 kilometre time-trial (TT) 
that participants were to complete as part of the experimental trials, and hence the 
results of these visits were not used in final analysis. Visits 4 and 5 were both 
experimental trials, identical other than the supplement that was consumed prior to the 
trial. Participants completed one bout of steady-state exercise followed by a 5km TT per 
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visit, once having supplemented with NR, and the other having supplemented with a 
placebo (cellulose).  
 
DETAILS OF LABORATORY VISITS 
VISIT 1.  
Participants had the opportunity to discuss the study with the investigators in more 
depth and ask any questions they may have had. If they decided to participate, they then 
signed informed consent, had anthropometric measures recorded, and completed the 
screening and health/activity questionnaire. If the individual was deemed eligible to 
partake in the study based on the inclusion/exclusion criteria, they then completed an 
exercise test on a cycle ergometer. 
Prior to the onset of the exercise test, participants completed a 5-minute warm-up period 
of cycling at 50 Watts (W). Participants then undertook an incremental exercise test, 
and began cycling at a resistance of 75W for 3 minutes. Every 3 minutes, investigators 
increased the resistance of the bike by 25W. Ratings of perceived exertion (RPE) were 
determined using a 6-20 Borg scale (Borg, 1973), and recorded during every 3-minute 
increment. However once participants reached 15 (‘Hard’) or above on this scale, 
workload was increased by 25W every 1 minute. Participants were instructed to 
continue cycling until they could not maintain a cadence above 60 revolutions per 
minute (RPM) or requested that the test was stopped (volitional fatigue). Thereafter, 
they completed a 5-minute cool down period of unloaded cycling. 
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Using a breath-by-breath metabolic cart (Vyntus CPX, Jaeger, CareFusion, Germany), 
respiratory variables were measured allowing the calculation of maximal oxygen 
consumption (VO2max, mL/min/kg), minute ventilation (VE) (L/min), VO2 (mL/min), 
VCO2 (mL/min) and the respiratory exchange ratio (RER). Prior to use, the metabolic 
cart was calibrated for volume using a 3 litre gas syringe, and was gas calibrated with 
commercial gases of known concentration.  
VO2max was calculated using 30-second averages from the metabolic cart output, with 
the maximum average value determined as the participants’ VO2max score. This output 
was also used to calculate the power at which each individual would be required to 
cycle at during the steady-state exercise in the experimental trials; a scatter graph of 
VO2 values at each power output during the incremental test was created, and from this 
the power in Watts corresponding to 55%VO2max was calculated.  
 
VISITS 2 AND 3. 
In a study by Sewell & McGregor (2008), the use of one familiarisation trial (20km TT) 
was reported to lower the variance shown between the subsequent three TTs completed 
by seven recreationally active adults (mean coefficient of variance = 3.4%). In order to 
ensure reduced levels of variance between experimental trials in the present study, it 
was decided participants would complete two familiarisation sessions prior to these. 
Results of these visits were however not used during analysis. 
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Following a 5-minute warm-up of cycling at 50W, the bike was programmed to the 
linear mode, and participants were instructed to complete a 5km self-paced TT, which 
typically lasted between 10-15 minutes.  
For each participant, the resistance added during the trial was determined using an alpha 
value that was calculated so that power output would require ~86%VO2max, whilst 
cycling at 80RPM (as used in Sewell & McGregor, 2008);  
Alpha = (0.86*Wmax) / 802  
Participants were provided with verbal encouragement, and feedback in regard to 
distance cycled every 1km, then 500m and 250m from the end. They were however 
blinded from time, power output (Watts) and RPM throughout the trial.  
 
VISITS 4 AND 5. 
Following their evening meal the night before each experimental trial (~8pm), 
participants were instructed to consume 1,000mg NR or placebo in the form of four 
250mg capsules. This dosing strategy was chosen based on the results of the first 
clinical NR trial in humans, in which it was concluded that NR works in a dose-
dependent fashion, with the greatest rise in NAD+ levels observed following the 
consumption of 1,000mg NR (Trammell et al., 2016). Additionally, in the n=1 study 
from Trammell et al. (2016), it was shown that following the consumption of a single 
1,000mg dose of NR, NAD+ levels in peripheral blood mononuclear cells (PBMC) rose 
significantly, remaining elevated for up to 24 hours post-consumption (Trammell et al., 
2016). Participants were provided with these capsules after the completion of visits 3 
32 
 
and 4, and were sent text message reminders to consume the supplements the evening 
before both trials. 
Upon arrival on the day of the trial, participants had a cannula (BD Venflon™, India)  
placed in a forearm vein to allow for a baseline and then repeated blood sampling 
during the experimental session. Participants then completed a 60-minute steady-state 
cycle at 55%VO2max (as calculated from Visit 1). The intensity of 55%VO2max was 
chosen based on evidence that moderate-intensity exercise is most likely to promote 
enhanced fat utilisation. Although variable between individuals, ‘Fatmax’ has been 
deemed to occur at exercise intensities ranging between 40% and 72%VO2max (Bergman 
& Brooks, 1999; Achten, Gleeson & Jeukendrup, 2002a). 
For five minute periods every 15 minutes during the trial (at 15, 30, 45 and 60 minutes), 
participants wore a mask connected to the metabolic cart to enable the collection of 
breath-by-breath data for analysis. During each of these five minute periods, RPE and 
heart rate (HR) (Polar RCX5, New York) were also recorded. After a 2-minute break 
following completion of the steady-state exercise, participants then completed a 5km 
self-paced time-trial, as they did in visits 2 and 3. These experimental visits lasted 
approximately two hours.  
Visit 5 was identical to visit 4, however participants consumed the alternative 
supplement prior to this visit. Both participants and investigators were blinded to 
supplement order, which was randomised. Visits 4 and 5 were separated by at least one 
week, to allow for wash-out of the supplement.  
Following each experimental trial, breath-by-breath data was extracted from the 
metabolic cart. From each of the five minute periods recorded, the first minute of data 
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was disregarded, and four minute averages were calculated for VE (minute ventilation), 





RANDOMISATION AND BLINDING 
Participants were enrolled by the study investigator, however participant trial order (NR 
or placebo supplement order) was randomly assigned by another researcher, who was 
not involved in participant recruitment, data collection or analyses. Randomisation was 
achieved using the free online research randomiser software (www.randomizer.org), 
which generated a random trial order for all (n=11) participants. The designated 
laboratory member labelled the supplements ‘A’ and ‘B’, and until all data collection 
was complete, only this laboratory member had access to the randomiser output and the 
record of which supplement carried each label. All relevant information was disclosed 
to the study investigator and participants following completion of all analyses. 
 




Following their third visit to the laboratory, participants were provided with either 
1,000mg NR or cellulose (placebo), dependent on their randomised trial order. They 
were then provided with 1,000mg of the remaining supplement following the 
completion of visit 4, and were instructed to consume this prior to visit 5, after a 
washout period of approximately seven days. This washout period was chosen based on 
the methodology of the first clinical NR trial in humans, in which twelve participants 
consumed a single dose of 100mg, 300mg and 1,000mg NR in a randomised order with 
a seven day washout period between data collection (Trammell et al., 2016). 
Supplements were given in the form of 250mg capsules, and participants were 
instructed to orally consume four the night before each trial (~12 hours prior); a total 
dose of 1,000mg per visit. The timing and size of the NR dose was based on the results 
of the first human NR trial, in which one male participant consumed 1,000mg NR for 
seven days (Trammell et al., 2016). Blood analysis showed that following just one 
1,000mg dose of NR, PBMC NAD+ levels were heightened significantly, peaking after 
7.7 hours. To allow participants a normal night of sleep, supplements were consumed 
~12 hours prior to exercise rather than 8 hours prior, however as NAD+ levels remained 
elevated up to 24 hours post-consumption in the pilot study (Trammell et al., 2016), this 
was deemed adequate.  
Both the experimental and placebo supplements were commercially available: 




 Cellulose: Microcrystalline Cellulose, Blackburn Distributions. For more 
information, please see http://www.blackburndistributions.com/microcrystalline-
cellulose-mcc-powder.html  
 
NUTRITION AND PHYSICAL ACTIVITY CONTROLS  
Participants were instructed to arrive fasted to visits 1, 4 and 5, having not consumed 
any food after 8pm the previous night. They were however permitted to drink ~300mL 
of water prior to these visits, to ensure they were sufficiently hydrated. As visits 2 and 3 
were familiarisations and completed purely for the benefit of the participant, these 
nutrition/activity controls were not applied. However, exhaustive activity and the 
consumption of alcohol, caffeine or any other supplement was prohibited in the 24 
hours leading up to all visits.  
One day prior to the first experimental visit (visit 4), participants were required to 
complete a food diary. They were then asked to replicate this diet as closely as possible 
on the day before their second experimental visit (visit 5). Participants were also 
required to provide the experimenters with a copy of this diary at visit 4. 
 
CANNULATION 
The cannula was inserted into a vein in the forearm upon arrival to the laboratory on 
visits 4 and 5. To allow for plasma, red blood cell (RBC) and PBMC analysis, 26mL (2 
x 10mL, 1 x 6mL) samples were taken at the onset of steady-state exercise, following 
completion of steady-state exercise, and upon completion of the 5km time-trial. At 15, 
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30 and 45 minutes into exercise, 6mL samples were taken for plasma and RBC analysis. 
In total, 6 blood samples (96mL in total) were taken throughout each visit. 
 
BLOOD PREPARATION 
PLASMA AND RBC:  
For all time points (baseline, 15, 30, 45, 60 and post-TT), 6mL blood was drawn into 
ethylenediamine tetraacetic acid (EDTA) collection tubes (BD, Plymouth, UK), 
inverted, and left to stand on ice until the experimental trial was complete. Upon 
completion of the trial, these tubes were centrifuged at 1,600xG at 4°C for 8 minutes 
(Thermo Scientific, Massachusetts, USA). Plasma was then extracted and transferred 
into 1.5mL tubes (Eppendorf, Germany). From the baseline, 60 and post-TT samples, 
100μL RBC was aliquoted into chilled 2mL tubes (Eppendorf, Germany), each 
containing 1mL 0.5M Perchloric Acid. All plasma and RBC samples were flash frozen 
in liquid nitrogen, then stored at -80°C until further analysis. 
PBMC:  
The 20mL (2 x 10mL) blood samples taken at baseline, 60 and post-TT time points 
were drawn into heparin collection tubes (BD, Plymouth, UK), inverted, and left to 
stand in ice until the experimental trial was complete. Samples were transferred into 
50mL conical centrifuge tubes (Falcon, Mexico), and then diluted 1:1 with Roswell 
Park Memorial Institute (RPMI) 1640 medium (Gibco™, Paisley, Scotland), and mixed 
via inversion. 5mL Ficoll-Pacque Plus (GE Healthcare, Uppsala, Sweden) was pipetted 
into 15mL conical tubes (Falcon, Mexico) and 10mL of blood/RPMI was pipetted 
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carefully on top of the Ficoll-Paque. Tubes were then centrifuged at 400xG for 30 
minutes at room temperature (22°C). 15mL concical tubes were then prepared with a 
small amount (approximately 2mL) of autoMACS Running Buffer (Miltenyi Biotec, 
Germany). The PBMC layer from the previously centrifuged 15mL tubes was carefully 
pipetted off, and decanted into the tubes containing autoMACS Running Buffer. The 
tubes were then filled with autoMACS Running Buffer, and centrifuged at 300xG for 10 
minutes at 4°C. Tubes were removed from the centrifuge, and the supernatant was 
poured away. Each remaining pellet was then re-suspended in 1mL freezing medium 
(90% fetal bovine serum, 10% dimethyl sulfoxide), and pipetted into 2mL tubes 
(Eppendorf, Germany) to be frozen. The tubes were transferred into a Mr. Frosty 





Plasma samples were analysed on an auto-analyser (iLAB650, Instrumentation 
Laboratory, Bedford, MA, USA) for non-esterified fatty acid (NEFA), lactate, glycerol 
(Randox Laboratories, County Antrim, UK) and glucose (Instrumentation Laboratory, 
Bedford, MA, USA) using commercially available kits. For each metabolite, 200μL of a 
control sample (CON) and a standard sample (CAL) were aliquoted into cuvettes and 




 NEFA: Human Assay Control 2 (HAC2) and HAC3 
 Lactate: HAC2 and HAC3 
 Glycerol: Glycerol CON 
 Glucose: SeraChem Control Level 1 (Sera1) and Sera2 
Reagents for each metabolite were made up according to the instructions supplied with 
the kits, and also placed in their assigned tray position. Before sample analysis, the 
auto-analyser was calibrated via analyses of the CON and CAL samples, and if the 
mean of these values was within the acceptable range (found on the instruction sheets), 
sample analysis could be undertaken. Prior to running the sample analysis, 200μL of 
each plasma sample was aliquoted into a cuvette and placed into the tray in the auto-
analyser. Samples were run in duplicate, and mean values were calculated for use 
during data analysis.  
The intra-assay (inter-assay) coefficient of variation (CV) for the above methods are as 
follows (based on analysis of 20 duplicate samples): NEFA, 3.34% (3.1%); lactate 
2.04% (3.9%); glycerol, 2.76% (5.9%) and glucose, 1.48% (5.9%) (Robinson, 2016). 
PBMC:  
PBMC samples were sent away to be analysed in order to measure the NAD+ 
metabolome, as described by Trammell et al. (2016). However due to time constraints, 







Total CHO and fat oxidation rates (g/min) were calculated from the rates of O2 and CO2 
production (L/min) recorded at baseline, using the following equations proposed by 
Frayn (1983): 
Carbohydrate oxidation (g/min) =4.55 x VCO2 – 3.21 x VO2 
Fat oxidation (g/min) =1.67 x VO2 – 1.67 x VCO2 
For VO2 and VCO2 values (L/min) obtained during SS exercise, the following equations 
proposed by Jeukendrup & Wallis (2005) were used, working under the assumption that 
protein oxidation during exercise is insignificant:  
Carbohydrate oxidation (g/min) = 4.210 x VCO2 – 2.962 x VO2 
Fat oxidation (g/min) = 1.695 x VO2 – 1.701 x VCO2 
 
STATISTICAL ANALYSIS 
Data analysis was performed using IBM SPSS (Version 23) software. Data are 
expressed as mean ± standard deviation (S.D.), and the significance level was set at p < 
0.05. A two-way repeated-measures analysis of variance (ANOVA) was used to assess 
the effects of time, condition and time*condition interaction effects for all steady-state 
exercise data (VO2, VCO2, RER, fat oxidation, CHO oxidation, HR, RPM and blood 
variables). Time trial performance was compared using paired-sample t-tests. Ryan-







The workload of 55%VO2max used throughout the 60-minute steady-state exercise 
corresponded to an average power output of 136±11 Watts. Participants cycled at the 
same fixed Watts for each of their experimental trials.  
 
OXYGEN CONSUMPTION AND CARBON DIOXIDE PRODUCTION 
During the steady-state exercise, five minute measurements of oxygen consumption 
(VO2) and carbon dioxide production (VCO2) were recorded at baseline, then every 15 
minutes during exercise (see Table 2).  
For both VO2 and VCO2, a main effect of time was shown (p = .000), yet there was no 
main effect of condition (NR vs. PLA) (p = .884 and p = .406, respectively) or a 
time*condition interaction (p = .422 and p = .451, respectively). Post-hoc analysis 
revealed that baseline VO2 values (NR: 0.39±0.07, PLA: 0.40±0.04) were significantly 
different from all other time points during exercise (NR: 15min 1.98±0.41, 30min 
2.02±0.41, 45min 2.04±0.39 and 60min 2.04±0.43, PLA: 15min 1.96±0.37, 30min 
2.01±0.37, 45min 2.02±0.38 and 60min 2.06±0.38, p < .05). VCO2 values at baseline 
(NR: 0.33±0.05, PLA: 0.34±0.03) also significantly differed from those during exercise 
(NR: 15min 1.79±0.33, 30min 1.79±0.33, 45min 1.80±0.32 and 60min 1.78±0.34, PLA: 
15min 1.82±0.38, 30min 1.82±0.35, 45min 1.8±0.35 and 60min 1.83±0.36, p < .05). 
There were however no significant differences between exercise time points (p > .05). 
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Table 2. Mean VO2 and VCO2 values for NR and placebo conditions at baseline and 
during steady-state exercise 
 NR PLA 
Time VO2 (L/min) VCO2 (L/min) VO2 (L/min) VCO2 (L/min) 
Baseline 0.39±0.07 0.33±0.05 0.40±0.04 0.34±0.03 
15 1.98±0.41* 1.79±0.33* 1.96±0.37* 1.82±0.38* 
30 2.02±0.41* 1.79±0.33* 2.01±0.37* 1.82±0.35* 
45 2.04±0.39* 1.80±0.32* 2.02±0.38* 1.8±0.35* 
60 2.04±0.43* 1.78±0.34* 2.06±0.38* 1.83±0.36* 
Values are expressed as mean ± S.D, n=11. *p < .001 vs. baseline values. 
 
RESPIRATORY EXCHANGE RATIO (RER) 
A main effect of time (p = .017) was seen in mean RER values, indicating that RER 
rose significantly with time (NR: Base 0.85±0.09, 15min 0.91±0.04, 30min 0.89±0.03, 
45min 0.88±0.03 and 60min 0.87±0.32, PLA: Base 0.85±0.56, 15min 0.92±0.04, 30min 
0.9±0.03, 45min 0.89±0.03 and 60min 0.89±0.03, see Figure 7). At no time points 
during exercise did values significantly differ from baseline (p > .05), however a 
significant difference was seen between each exercise time point (p < .05). No 
interaction effect or main effect of condition was seen, however (p = .455 and p = .648, 











Figure 7. Mean RER values measured at baseline (0 min) and throughout the 60-minute SS 
exercise for NR (○) and placebo (■) conditions. *p < .05 vs. time point. Values are means ± 
S.D., n = 11. 
 
FAT AND CARBOHYDRATE OXIDATION 
As expected, whole-body fat oxidation increased from baseline and throughout the 60-
minute steady-state exercise with a significant effect of time (p = .000, see Figure 8A), 
and significant differences between each time-point (NR: Base 0.10±0.06, 15min 
0.31±0.19g/min, 30min 0.37±0.18 g/min, 45min 0.40±0.17 g/min and 60min 0.44±0.19 
g/min, PLA: Base 0.10±0.04, 15min 0.24±0.10 g/min, 30min 0.31±0.10 g/min, 45min 
0.36±0.11 g/min and 60min 0.38±0.08 g/min, p < .05). Consequently, whole-body CHO 
oxidation significantly decreased throughout exercise with a main effect of time seen (p 
= .000, see Figure 8B), however there was no significant difference shown between 45 














and 60 minute time points (p > .05). No interaction effect (p = .309 and p = .310), nor 
main effect of condition (p = .211 and p = .249) was seen for either fat or CHO 
oxidation, respectively, indicating that NR supplementation had no significant effects 
















































Figure 8. Fat (A) and CHO (B) oxidation rates at baseline (0 min) and throughout the 60-
minute SS exercise, for NR (○) and placebo (■) conditions. *p < .05 vs time point (excluding 
45 vs. 60 for CHO). Values are means ± S.D., n = 11. 
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The mean contribution of substrates at baseline and at each time-point during the 
steady-state exercise is shown in Figure 9. With NR supplementation, the overall 
contribution of fat to total substrate utilisation was 22.3±9.0%, and 19.6±7.3% with 
placebo, however this difference was not significant and therefore did not elicit a main 
effect of condition (p = .429) or an interaction effect (p = .647). But as expected, there 
was a main effect of time (p = .008), with significant differences shown between all 
time points (p < .05), excluding between baseline and 45 min, and baseline and 60 min. 

































Figure 9. Mean contribution of substrate (FAT, CHO) as a percentage at baseline and 
throughout the 60-minute SS exercise, for NR (□) and placebo (■) conditions. *p < .05 vs time 






Due to equipment malfunction, HR data is only reported for 10 out of 11 participants. A 
significant increase in HR occurred between baseline and all exercise time points, and 
between 15min and all remaining exercise time points (NR: Base 70±11 bpm, 15min 
122±9 bpm, 30min 126±9 bpm, 45min 127±11 bpm and 60min 130±13 bpm, PLA: 
Base 68±7, 15min 123±11 bpm, 30min 126±13 bpm, 45min 128±11 bpm and 60min 
131±14 bpm, p < .05), contributing to the main effect of time shown (p = .000, see 
Figure 10A).  
The consumption of NR had no effect on HR at baseline or during exercise however, as 
there was no main effect of condition or an interaction effect shown (p = .857 and p = 
.534, respectively).  
 
RATINGS OF PERCEIVED EXERTION 
RPE values elicited a significant main effect for time (p = .015) in which they increased 
throughout exercise (Figure 10B), however no significance was shown between any 
specific time points during post-hoc analysis (p > .05). There was also no 
time*condition interaction effect seen (p = .813), nor was there a main effect of 
condition (p = .267), meaning perceived exertion was not affected by the 
supplementation of NR.  
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Figure 10. Mean HR values (A) measured at baseline (0 min) and throughout the 60-minute SS 
exercise (n=10) and mean RPE values (B) throughout exercise (n=11), for NR (○) and placebo 




TIME TRIAL PERFORMANCE 
T-test analysis indicated that there was no significant differences in TT performances 
between the participants’ first and second experimental trials (p = .85). This confirms 
that the two familiarisation TTs undertaken by all participants prior to these trials were 
sufficient at eliminating a learning effect. 
One participants’ TT data was excluded from the results, due to equipment malfunction. 
The average time to completion of a 5km TT following the consumption of placebo and 
NR were 823.4±250.0 and 819.5±239.8, respectively (Figure 11). Hence, the 
supplementation of NR had no effect on performance as no statistical difference was 
seen between these results (p = .72).  
The large variability between participants is clear when studying the individual data 
points also presented in Figure 11, although individuals did show no significant 

























Figure 11. Mean 5km TT performance times for NR and placebo conditions, with individual 
participant data also displayed. Values are means ± S.D., n = 10. 
 
PLASMA METABOLITES  
Figure 12 shows the effects of both time and condition (NR or placebo) on plasma 
NEFAs, glycerol, glucose and lactate. Due to some unattainable samples from one 
participant, all blood data from this participant was not included in analyses. 
Plasma NEFA, lactate, glycerol and glucose concentrations were all unaffected by NR 
supplementation, as there was no significant main effect of condition (p = .435, p = 
.521, p = .162 and p = .811, respectively) or a time*condition interaction (p = .237, p = 
.838, p = .620 and p = .756, respectively) shown for any metabolite.  
However, there was a main effect of time shown for plasma NEFA, lactate and glycerol 
(p = .002, p = .000 and p = .000, respectively). Average NEFA concentration decreased 
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from baseline with the onset of steady-state exercise with a significant difference seen 
between baseline and 15 min (p < .05), then increased with time during exercise, with 
significant differences shown between 15 and 45, 15 and 60, and 30 and 60 min time 
points (p < .05). Immediately following the TT, NEFA concentrations tended to 
decrease again, although this was not significant (Figure 12A, p > .05).  
Plasma lactate concentration was significantly different between baseline and all 
remaining time points (p < .05), but did not differ throughout the 60-minute steady-state 
exercise (p >.05). However, following the high-intensity 5km TT, lactate concentration 
significantly increased (Figure 12B), with differences shown between post-TT and all 
other time points, (p < .05). These differences together contributed to a main effect of 
time (p = .000).  
There was an increase in plasma glycerol concentration with time during steady-state 
exercise, and this continued to rise post-TT. A main effect of time was seen (p = .000), 
with significant differences shown between all time points excluding between baseline 
and 15 min (Figure 12C, p < .05). Finally, plasma glucose concentrations did not differ 
with time or supplement, with no main effect of time (p =.068) nor condition (p = .811) 
shown despite there being significant differences shown between baseline and both the 








































































































Figure 12. Mean plasma concentrations of NEFA (A), lactate (B) glycerol (C) and glucose 
(D) at baseline (0 min), throughout the 60-minute SS exercise and immediately post-TT, for 
NR (○) and placebo (■) conditions. *p < .05 vs time points as described in text. Values are 






The present study is the first to investigate the effects of Nicotinamide Riboside 
supplementation on humans during exercise, with a specific focus on substrate 
metabolism and performance. This study expands on the limited research surrounding 
NR consumption in humans, as the effects of this substance during exercise have only 
been examined in rodents thus far (Canto et al., 2012; Kourtzidis et al., 2016). The 
primary aims of this study were to investigate whether the consumption of a single dose 
of NR alters substrate utilisation during moderate-intensity exercise, and performance 
during a high-intensity 5km TT in recreationally-active males, in comparison to a 
placebo. 
It was shown that the consumption of NR had no effect in the present study, with no 
significant main effects of condition or time*condition interactions shown for any 
outcome measure. Although main effects of time were reported for almost all measures, 
NR in no way enhanced these effects, opposing the hypotheses. The intensity and 
duration of the steady-state exercise were sufficient to alter substrate utilisation, with a 
significant increase in fat oxidation and parallel decrease in CHO oxidation seen 
throughout exercise (see Figure 8). Both blood analysis and RER results support these 
findings, with plasma NEFA and plasma glycerol concentrations significantly 
increasing (see Figure 12), and RER values significantly decreasing with exercise (see 
Figure 7), indicating that the use of fats as an energy source was enhanced with time. 
Steady-state exercise also gave rise to significant increases in both HR and RPE, 
however there were no differences seen between the NR and placebo conditions for any 
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of these measures (see Figure 10). No significance was shown between the two 
conditions when comparing TT performance either, hence confirming that NR 
consumption does not improve performance in a 5km TT following a bout of steady-
state exercise (see Figure 11). 
As the first study of its kind, and one of very few trials to investigate NR in human 
participants, the hypotheses proposed in the present study are based on limited 
evidence. Hence, the results of this study should not be seen in a negative light, as they 
in fact provide a wider insight into the effects of NR in humans - specifically in exercise 
- and also offer a foundation for future research to build upon. Modifications to the 
design of this study are necessary to test the full potential of NR with exercise, whether 
that be altering the exercise intensity, duration or mode, changing the dosing strategy or 
combining supplementation with long-term exercise training.  
During prolonged steady-state cycling, a gradual depletion of muscle glycogen usage 
and a shift towards fat oxidation occurs (Watt et al., 2002). Hence, reducing the 
intensity but increasing the duration of exercise would likely promote fat oxidation 
more so than during the 60-minute bout in the present study.  
It is possible that in order to see an effect of NR supplementation, intra-muscular NAD+ 
needs to be altered. The dosing strategy used in the present study is known to influence 
the NAD+ profile in the blood (Trammell et al., 2016), however no data exists as to how 
this relates to skeletal muscle thus far. It is possible that longer term NR 
supplementation would be required to alter intra-muscular NAD+ levels. 
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Finally, the combination of exercise training and long-term NR supplementation has the 
potential to further enhance the physiological adaptations seen from training alone, due 
to the positive effect both components can have on the activity of sirtuins. 
 
SUBSTRATE UTILISATION 
It was hypothesised that fat oxidation may increase more so during steady-state exercise 
in the NR condition than with a placebo, due to the downstream effects of enhanced 
deacetylation of SIRT3, in response to heightened NAD+ levels (Hirschey et al., 2010). 
However, as no significant differences were seen between conditions, it appears this 
was not the case. As the first human study to investigate the effects of NR on substrate 
metabolism, this hypothesis was based on the evidence that NR has the ability to boost 
SIRT3 activity in mice (Canto et al., 2012), which upregulates various metabolic 
enzymes, subsequently increasing fat oxidation. In this study by Canto et al. (2012) 
however, NR was administered long-term, in contrast to the single dose consumed in 
the present study.   
Based on the results of Trammell et al. (2016), it can be assumed that NAD+ levels in 
the blood of participants in the present study were enhanced following the consumption 
of NR. Yet based on the lack of significant differences between conditions, it appears 
that this heightened NAD+ level in the blood is not great enough to have an effect on 
substrate utilisation. It is possible that an increased NAD+ level in tissue, such as 
muscle or liver, is required for NR to alter substrate use. Chronic NR supplementation 
in rodents has been seen to increase NAD+ levels in both liver and muscle tissue (Canto 
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et al. 2012), suggesting that a longer supplementation period may be necessary to 
induce any significant changes to health and/or performance.  
Despite the significant increase in fat oxidation throughout steady-state exercise in the 
present study, and consequent decrease in CHO oxidation, it is likely that the duration 
and/or intensity of this exercise did not lead to maximal rates of fat oxidation. The 
intensity of 55%VO2max used in the present study, based on previous Fatmax studies 
(Achten, Gleeson & Jeukendrup, 2002a; Venables, Achten & Jeukendrup, 2005; 
Randell et al., 2017; Fletcher et al., 2017) should be sufficient for promoting near 
maximal fat oxidation. Hence, it seems that the duration of steady-state exercise 
undertaken was not optimal. In a study by Watt et al. (2002), substrate utilisation was 
monitored throughout a four hour cycle at 55%VO2max in seven endurance-trained men. 
It was shown that fat oxidation rates surpassed those of CHO only after participants had 
been exercising for over 120 minutes, and by the end of the four hour cycle, the rate of 
fat oxidation was markedly higher than that of CHO. These results were supported by 
the considerable changes seen in substrate use throughout exercise - both plasma FFA 
and plasma glycerol use increased progressively as time went on, whereas muscle 
glycogen decreased substantially. Hence, it would appear that the 60-minute exercise 
bout undertaken in the present study was not a powerful enough stimulus to promote fat 
oxidation to the desired level. It is possible that if fat oxidation had been enhanced more 
so - by increasing the duration of the steady-state exercise - a difference between the 
NR and placebo conditions may have been shown.  
The utilisation of substrates is controlled by numerous hormonal, metabolic and neural 
mechanisms (Esséen, 1977). Whilst it cannot be ruled out entirely, it appears that NR 
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does not have the capacity to alter hormonal activity, unlike other ‘fat burning’ 
supplements, such as caffeine and green tea. Although results regarding an alteration in 
substrate utilisation in humans are ambiguous, there is evidence that caffeine works to 
enhance sympathetic nervous system activity, heightening adrenaline levels which can 
hence increase lipolytic rate and FA availability (Jeukendrup & Randell, 2011). Green 
tea works in a similar manner, due to its high capacity of catechin polyphenols 
(Jeukendrup & Randell, 2011). These catechins directly inhibit the enzyme catechol-O-
methyltransferase, which works to lower noradrenaline levels. This hence has the 
potential to increase FA oxidation, by acutely enhancing the stimulation of the 
sympathetic nervous system (Jeukendrup & Randell, 2011). The way in which these 
substances work appears to differ greatly from the way in which NR does, as a change 
in NAD+ levels does not directly alter catecholamine secretion. It seems that the 
speculated molecular changes alone brought about by acute NR supplementation, if any, 
were not potent enough to alter substrate utilisation in the present study. 
 
TIME TRIAL PERFORMANCE 
The supplementation of NR did not affect 5km TT performance following a 60-minute 
bout of moderate-intensity steady-state exercise, with mean performance times of 
819.5±239.8 seconds in the NR condition, and 823.4±250.0 seconds with the placebo. 
The hypothesis that TT performance would be improved following NR supplementation 
was based on the premise that fat oxidation would be increased during the 60-minute 
steady-state exercise, sparing muscle glycogen - the dominant fuel source at higher 
intensity exercise (Van Loon et al., 2001) - and hence allowing participants to exert a 
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higher power output for longer during the TT. However, fat oxidation was not enhanced 
by NR consumption during the steady-state exercise, supporting the non-significant 
difference between TT performances. Based on the results of the aforementioned study 
by Watt et al. (2002), it appears that the duration of the steady-state cycling in the 
present study was not long enough to promote maximal rates of fat oxidation, allowing 
for the attenuation of muscle glycogen use in order for it to later be spared in the TT. In 
fact, it seems the steady-state exercise would have needed to double in duration for this 
mechanism to work, with Watt et al. (2002) reporting a decline in CHO oxidation 120 
minutes into exercise, corresponding with the decrease in muscle glycogen use also 
seen.  
Although sparse, previous studies also investigating the effects of NR supplementation 
on exercise performance in rodents have produced contrasting results (Kourtzidis et al., 
2016; Canto et al., 2012). Following a three week NR supplementation period, rats 
tended to perform worse in an incremental swimming test compared to a control group 
(Kourtzidis et al., 2016). Conversely, in high-fat diet fed mice, endurance performance 
in a treadmill exercise test was significantly improved after long-term NR 
supplementation (Canto et al., 2012). An alternative approach to increasing the NAD+ 
pool was employed by Frederick et al. (2014), in which the enzyme NAMPT was 
overexpressed in mice, who were then assessed via exercise tolerance, voluntary 
running and grip strength tests. Despite increasing the NAD+ content of skeletal muscle 
by 50%, no alterations in oxygen consumption, running capacity, voluntary running 
activity nor strength were observed in mice with NAMPT overexpression. Hence, the 
improved performance seen in Canto et al. (2012) is unlikely to be due to purely 
muscle-specific increases in NAD+.   
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The discrepancy in the results of the above studies could partly be due to 
methodological differences, such as type of exercise, the animal model used, or the way 
in which the supplement was administered. However, as Kourtzidis et al. (2016) also 
discuss, there appears to be a possible explanation for a decreased exercise performance 
following NR consumption, in the form of early Na studies (Murray et al., 1995; 
Pernow & Saltin, 1971). NR and Na are similar in that both are NAD+ precursors, and 
hence work to enhance NAD+ levels. There is evidence however that Na blunts the 
exercise-induced rise in plasma FFAs, therefore limiting fat oxidation throughout 
exercise and accelerating the onset of fatigue (Murray et al., 1995; Pernow & Saltin, 
1971). The effects of Na consumption during a steady-state bout of cycling at 
68%VO2peak followed by a 3.5 mile performance test were investigated by Murray et al. 
(1995). It was reported that the increase in FFAs during the pre-load exercise was 
blunted, with participants eliciting a higher RER post Na ingestion. Despite a lack of 
significance between the water placebo trial and the water+Na trial, the authors propose 
that Na administration may have actually been detrimental to performance, supporting 
the results of Kourtzidis et al. (2016). In the present study however, plasma NEFA 
levels were comparable between groups, suggesting the blunting of plasma FFAs did 




Based upon the results of the majority of previous NR research, this substance appears 
to work optimally when supplemented long term, and in populations with a deficiency 
in NAD+ prior to consumption. The results of the present study support this, as no 
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significant differences were seen in any measure between NR and placebo conditions 
following consumption of a single dose of NR in young, healthy participants. In rodent 
studies, the chronic administration of NR in clinical populations has proven extremely 
successful, with significant improvements seen in various diseased models, including 
rodents with Alzheimer’s (Gong et al., 2013), mitochondrial myopathy (Khan et al., 
2014) and muscular dystrophy (Ryu et al., 2016). Many of the diseases targeted by NR 
research are age-related, and ageing is associated with an accumulation of DNA damage 
(Brace et al., 2016). Hence, NAD+ levels are decreased due to heightened PARP 
activity (Malanga & Althaus, 2005), possibly providing NR with capacity to build upon 
these levels, unlike in healthy participants such as those used in the present study. This 
expanding body of research provides an exciting insight into the potential uses of NR in 




As the first study of its kind, there is huge scope to expand on this in order to investigate 
fully the potential benefits of NR supplementation in humans. The effects of a single 
dose of NR were explored in the present study finding no significant results, and hence 
it would be logical for a longer supplementation period to be implemented in future 
research. 1,000mg NR was administered daily for seven consecutive days in the first 
human study of NR (n=1) (Trammell et al., 2016). Although PBMC NAD+ 
concentration peaked 7.7 hours post-ingestion of the first dose, subsequent 
measurements – one prior to the second dose and one 24 hours following the seventh 
and final dose – show that NAD+ concentration was on the rise between these two 
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points. The same pattern was shown with Nam and NAAD, and also with MeNam, 
Me4PY and Me2PY, indicating enhanced NAD+-consuming activity. It is plausible that 
a supplementation period in excess of seven days may help to continue this rise in 
NAD+ metabolome concentrations. A chronic and sustained increase in NAD+ levels in 
the blood prior to a single bout of exercise should, in theory, give rise to more 
pronounced differences in substrate utilisation in comparison to the single dose 
administered in the present study. Building upon the n=1 study by Trammell et al. 
(2016) by recruiting a larger group of participants and administering them with NR for 
an extended period of time (e.g. four to six weeks) would allow for the establishment of 
the dose:response relationship of NR consumption. Determining the effects of long-term 
NR supplementation on the NAD+ metabolome would be extremely beneficial for the 
future of NR research. 
Supported by research from Watt et al. (2002), a steady-state exercise bout of between 
90-120 minutes would likely promote higher levels of fat oxidation and decreased levels 
of CHO oxidation, compared to those reported after 60 minutes of exercise in the 
present study. Future research should investigate the effects of NR on substrate 
metabolism during longer bouts of exercise, as it may be possible that with higher rates 
of fat oxidation, a difference between the placebo and NR condition would be seen. 
With the protocol used in the present study, whether or not any differences in 
performance were shown between conditions in the 5km TT was largely dependent on 
whether a main effect of condition was shown for substrate utilisation during the steady-
state exercise. With an alternative protocol in which the duration of steady-state 
exercise is increased, the possibility of muscle glycogen sparing occurring with NR 
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supplementation may be enhanced. Hence, the likelihood of NR positively affecting TT 
performance would also be heightened.  
The future of NR research should also include the combination of long-term 
supplementation and exercise training. Alone, repeated bouts of exercise are capable of 
inducing a variety of physiological adaptations that together work to improve both 
performance and health (Jones & Carter, 2000). One of these adaptations is the 
increased utilisation of fat as a fuel source during both rest and exercise (Jeukendrup & 
Aldred, 2004), partly due to the enhanced activity of various TFs, co-activators and 
enzymes - including sirtuins. As SIRT1 and SIRT3 are NAD+-dependent, long-term NR 
supplementation should further increase deacetylation of these energy sensors in various 
tissues, as seen in mice in the study by Canto et al. (2012). Hence, the synergistic 
effects of supplementation and training together have the potential to further enhance 
the adaptations – including increased fat oxidation - seen from exercise training alone. 
In the present study, diet one day prior to the first experimental trial was recorded, then 
replicated the day prior to the second trial. However, when investigating a supplement 
which is found naturally in foods, the habitual diet of its consumers is likely to have an 
impact on the proficiency of the supplements’ effects. Hence, the recording of habitual 
diet and a longer period of dietary control prior to experimental trials, where meals were 
provided by the experimenters, would have enhanced reliability. However, this was 
outside the scope of this study. In future NR research, it would be advantageous to 
monitor and control dairy intake especially, as NR is found naturally in cow’s milk 
(Bieganowski & Brenner, 2004). The completion of a two week food diary prior to the 
onset of a study would allow for the exclusion of participants who consume above-
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average levels of dairy products, as these individuals may have naturally higher levels 
of NR present in their blood and/or tissues.  
 
CONCLUSION 
To conclude, the present data suggests that a single 1,000mg dose of NR has no effect 
on substrate utilisation in humans, during a 60-minute bout of steady-state cycling, or 
on 5km TT performance. Despite the significant increase in fat oxidation and 
subsequent decrease in CHO oxidation seen throughout exercise, no significant 
differences were shown between conditions, with both RER and blood plasma measures 
supporting this. It is probable that a single dose of NR is insufficient in heightening 
NAD+ levels in tissues such as skeletal muscle and liver, and hence is unable to 
enhance any mechanisms in which NAD+ plays a role – such as increasing the 
deacetylation of sirtuins. Additionally, unlike other ‘fat burning’ substances that appear 
to act via enhancing the activity of the sympathetic nervous system (Jeukendrup & 
Randell, 2011), NR does not appear to have the capacity to alter hormonal activity. 
Alterations to the present study design such as a longer-term supplementation period, an 
increased duration of steady-state exercise or the incorporation of exercise training into 
the protocol would be beneficial to further test the capacity of NR in humans during 
exercise, and as a possible ergogenic aid. Furthermore, any insight into the way in 
which NR works in humans is advantageous - with evidence demonstrating its success 
in rodents with diabetes, Alzheimer’s, mitochondrial myopathy and more, it seems NR 
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